It's a slam-dunk for Boston Scientific, and I think there are implications for the rest of the industry.
Strong leadership and better communication would likely turn it around within 18 to 24 months.
We expect the company to be a cardiovascular powerhouse, worth more together than on a stand-alone basis.
Eighty dollars a share is certainly a fair price for this business that we suspect is not nearly as damaged as the media coverage would suggest. It becomes increasingly difficult for JJ to follow Boston's lead on price.